| Detected | Trial | Change |
|---|---|---|
| 2026-06-06 | NCT07116031 A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) |
Trial sites expanded: 30 -> 33 locations |
| 2026-05-23 | NCT07116031 A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) |
date change Primary completion moved earlier: 2031-02-28 -> 2028-09-25 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-11 | NCT07643025 Belumosudil With Ruxolitnib as Second Line Therapy for Chronic Graft Versus Host Disease… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07135973 | A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above… | Chronic Graft Versus Host Disease | Not Yet Recruiting |
| Phase 3 | |||
| NCT06082037 | A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants… | Lung Transplant Rejection | Recruiting |
| Phase 2 | |||
| NCT07006506 | A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a… | Graft Versus Host Disease | Recruiting |
| NCT06046248 | Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease | Chronic Graft Versus Host Disease | Recruiting |
| NCT06476132 | Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung… | Lung Transplant | Recruiting |
| NCT05996627 | Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host… | Chronic Graft Versus Host Disease | Recruiting |
| NCT07116031 | A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) | Chronic Graft Versus Host Disease | Recruiting |
| NCT05922761 | BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) | Bronchiolitis Obliterans Syndrome | Recruiting |
| NCT07643025 | Belumosudil With Ruxolitnib as Second Line Therapy for Chronic Graft Versus Host Disease… | cGVHD | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT04643002 | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | Plasma Cell Myeloma Refractory | Recruiting |
| Phase 1 | |||
| NCT07484113 | IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD | cGVHD | Not Yet Recruiting |